SPRINT, NCT04256707 / 2021-000617-16: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment |
|
|
| Recruiting | 1/2 | 120 | RoW | Selinexor 100 mg, Xpovio®, Docetaxel, Taxotere®, Pembrolizumab, Keytruda®, FOLFIRI, Selinexor 40 mg, Selinexor 80 mg, Selinexor 60 mg | Karyopharm Therapeutics Inc | Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors | 03/25 | 03/25 | | |
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments |
|
|
| Recruiting | N/A | 2000 | Europe, US, RoW | Plasma sample collection | OncoHost Ltd. | Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma | 10/29 | 10/29 | | |
